Aldosterone in Diabetic Nephropathy

Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy.

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00870402

Acronym

ALDODN

Enrollment

160

Registered

2009-03-27

Start date

2009-03-31

Completion date

2010-03-31

Last updated

2009-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy

Keywords

aldosterone, albuminuria, diastolic disfunction, hyperkalemia

Brief summary

The purpose of this study is to determine whether spironolactone are effective in the reduction of albuminuria and diastolic disfunction of subjects with diabetic nephropathy.

Interventions

DRUGSpironolactone

25 mg per day for 9 months

DRUGPlacebo

Placebo 1 tablet per day for nine months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

30 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Diabetic subjects with maximum ten years after diagnostic * Diabetic nephropathy with albuminuria * Normal renal function * Diastolic disfunction * Taking a IECA or ARA drug family previously

Exclusion criteria

* Diabetics subjects with macroangiopathy * Acute coronary syndrome in the three months before * Hyperkalemia \> 5.5 mEq/L * Pregnancy

Design outcomes

Primary

Measure	Time frame
Reduction of albuminuria	9 months

Secondary

Measure	Time frame
Reduction of diastolic disfunction	9 months

Countries

Chile

Contacts

Primary ContactFrancisco G Espinoza, MD

fespinoz@mi.cl56 - 2 -91380529

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026